Q-omics provides the consensus-scored GP1BA profile across patient tissues and cancer cell-line models. GP1BA expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GP1BA is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, GP1BA RNA expression shows 18,294 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where GP1BA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GP1BA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GP1BA survival associations across molecular data types. GP1BA RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GP1BA RNA expression–survival associations across cancer types. High GP1BA expression shows unfavorable associations in ACC and THCA, but favorable associations in HNSC, BRCA, SKCM and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GP1BA RNA expression.
This table summarizes GP1BA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GP1BA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GP1BA shows lower tumor expression in COAD, THCA, LUSC, BLCA, LUAD and HNSC. The COAD box plot shows higher GP1BA RNA expression in normal versus tumor tissue (log2 FC = −0.562, t-test p < 0.001).
This table shows molecular features associated with GP1BA in patient tissues and cancer cell lines. In patient samples, GP1BA shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GP1BA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
